Last update 17 May 2025

Lofacimig

Overview

Basic Info

Drug Type
Nanobody
Synonyms
KN 060, KN-060, KN060
Target
FXIa
Action
inhibitors
Mechanism
factor XIa inhibitors(factor XIa inhibitors)
Therapeutic Areas
Cardiovascular Diseases
Active Indication
Venous ThromboembolismEssential Hypertension
Inactive Indication-
Originator Organization
Suzhou Alphamab Co., Ltd.Suzhou Alphamab Co., Ltd.
Active Organization
Suzhou Alphamab Co., Ltd.Suzhou Alphamab Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

4
Clinical Trials associated with Lofacimig
NCT06180889
/ RecruitingPhase 2
An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.
CTR20222339
/ CompletedPhase 1
评估KN060注射液在中国健康受试者中安全性、耐受性、药代动力学和药效学的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of KN060 injection in healthy Chinese subjects
ChiCTR2200056926
/ SuspendedPhase 1IIT
Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060 injection in healthy Chinese subjects
100 Clinical Results associated with Lofacimig
Login to view more data
100 Translational Medicine associated with Lofacimig
Login to view more data
100 Patents (Medical) associated with Lofacimig
Login to view more data
100 Deals associated with Lofacimig
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Venous ThromboembolismPhase 2
China
Suzhou Alphamab Co., Ltd.Suzhou Alphamab Co., Ltd.
19 Dec 2023
Essential HypertensionPhase 1
China
Suzhou Alphamab Co., Ltd.Suzhou Alphamab Co., Ltd.
12 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free